In contrast, the non-peptide B2R antagonist WIN 64338 showed promising growth inhibitory activity against all three GBM cell lines (Figure 11b), confirming the potential involvement of B2R signaling in GBM proliferation. This evidence concerns the gene BDKRB2 and glioblastoma.